- News
- Announcements
Announcements
Current & archive
Mental health screening of adults in primary care
With approximately one in five Austrian adults affected by mental illness annually, primarily depression (10%), anxiety disorders (7%), and substance use disorders (12%), screening in primary care settings could help identify and treat affected individuals early. Based on systematic reviews and evidence-based guidelines, this report analyses the evidence for mental health screening in primary care, identifies available screening tools, and discusses the requirements for implementing screening.
Publication: HTA Project Report No. 159: https://eprints.aihta.at/1544
Contact: Julia Kern
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you seven new Fact Sheets.
Fact Sheet Nr. 184 (July 2024)
Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)
Fact Sheet Nr. 185 (July 2024)
Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC)
Fact Sheet Nr. 186 (July 2024)
Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2?negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
Fact Sheet Nr. 187 (July 2024)
Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet Nr. 188 (July 2024)
Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma
Fact Sheet Nr. 189 (July 2024)
Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet Nr. 190 (July 2024)
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC
Uptake of Mental Health Benefits in Women Before and During the Perinatal Period: An Analysis of Austrian Health Insurance Data
On average, one in five women suffer from a mental illness during the perinatal period (pregnancy up to 1 year after birth. So far, it has been unknown how many women claim mental health services during this period. The analysis of pseudonymised insurance data revealed that around 20% of women in Austria who gave birth in 2017 and 2018 used at least one of five examined mental health services during the perinatal period. However, very few specialised perinatal mental health services are available in Austria, with regional disparities. The quality of existing services should be evaluated, and gaps in care need to be closed.
Publication: HTA Project Report No. 154: https://eprints.aihta.at/1535/
Contact: Ingrid Zechmeister-Koss
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 180 (June 2024)
Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)
Fact Sheet No. 181 (June 2024)
Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)
Fact Sheet No. 183 (June 2024)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)
Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer
This update report assesses three alternative treatments to radical therapies for localised prostate cancer (PCA): irreversible electroporation (IRE) uses electrode needles to target and destroy carcinoma tissue; stereotactic radiation therapy (SBRT) and proton therapy (PT) are forms of external beam radiation therapy, SBRT delivers high dose radiation in fewer fractions than conventional or moderate fractionation radiation, while PT delivers high-dose ionizing radiation with great precision.
The current evidence remains insufficient to conclude that IRE, SBRT, and PT improve outcomes in terms of survival and quality of life, as well as the avoidance of radical invasive procedures like prostatectomy, compared to conventional therapies. Recent RCTs on SBRT show minor differences in survival rates compared to conventional fractionation radiation in low- and intermediate-risk PCa. Further research is necessary for definitive conclusions.
Publication: Project Report No.: 107/1. Update: https://eprints.aihta.at/1530/
Contact: Judit Erdös
Evaluation of individual medical procedures - Reports 2024
We are pleased to introduce our new reports.
Decision Support Documents 2024:
- DSD 139: Caval valve implantation for severe tricuspid regurgitation https://eprints.aihta.at/1525
- DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia https://eprints.aihta.at/1526
- DSD 141: Thermoablation for benign thyroid nodules https://eprints.aihta.at/1527
+ 2 Updates
- DSD 24: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3. Update 2024 https://eprints.aihta.at/1528
- DSD 45: Renal denervation (RDN) in patients with treatment resistant hypertension. 2. Update 2024 https://eprints.aihta.at/1529
Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024
Point of care tests (POCTs) for troponin (Tn) and D-Dimer enable rapid diagnostics near patients. Tn-POCTs are used when there is a suspicion of acute coronary syndrome (ACS) and D-Dimer-POCTs are used when there is a suspicion of venous thromboembolism (VTE).
The aim of this report is to evaluate the clinical utility of the two POC diagnostics, D-Dimer and troponin, in primary care.
Publication: HTA Project Report No. 124, 1. Update 2024: https://eprints.aihta.at/1524/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 177 (May 2024)
Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)
Fact Sheet No. 178 (May 2024)
Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 179 (May 2024)
Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you six new Fact Sheets.
Fact Sheet No. 171 (April 2024)
Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)
Fact Sheet No. 172 (April 2024)
Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer
Fact Sheet No. 173 (April 2024)
Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)
Fact Sheet No. 174 (April 2024)
Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma
Fact Sheet No. 175 (April 2024)
Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion
Fact Sheet No. 176 (April 2024)
Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 168 (March 2024)
Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas
Fact Sheet No. 169 (March 2024)
Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours
Fact Sheet No. 170 (March 2024)
Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)
